Anti-Epac1/RAPGEF3 Polyclonal Antibody for WB, ELISA - O95398

Core Product Specifications and Parameters

Biological Background: Epac1/RAPGEF3 Function and Localization

• Epac1, encoded by RAPGEF3, is a cAMP-activated guanine nucleotide exchange factor for the small GTPases RAP1A and RAP2A.
• It functions as a key mediator of cAMP signaling, regulating processes such as angiogenesis, endothelial barrier function, and actin cytoskeleton remodeling.
• Epac1 assembles a signaling complex with PDE3B and PIK3R6 that activates the PI3K gamma complex, contributing to angiogenic responses.
• The protein plays a critical role in the dynamic control of endothelial barrier integrity via a Rho-independent pathway, influencing cell-cell junction actin organization.
• Epac1 is localized to the endomembrane system and is widely expressed, with highest levels in adult kidney, heart, thyroid, brain, and fetal kidney.
• Post-translational modifications include phosphorylation; the protein contains cAMP-binding and nucleotide-binding domains, and alternative splicing generates multiple isoforms.
• Keywords: Guanine-nucleotide releasing factor, cAMP-binding, Phosphoprotein, Membrane, Angiogenesis.

Experimental Guidance and Technical Tips

• The immunogen corresponds to the N-terminal region (aa 1–200) of human Epac1, which includes part of the regulatory cAMP-binding domain. For functional studies, consider that antibody binding may compete with cAMP or protein interactions.
• In Western blotting, endogenous Epac1 is expected at approximately 104 kDa. Additional lower bands may represent splice variants or proteolytic fragments; validate in the relevant model system.
• Confirm cross-reactivity in mouse samples, as indicated, and optimize antibody dilution and blocking conditions based on endogenous expression levels in your target tissue or cell line.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides diagnostic manufacturers, labs, and research institutes with one-stop access to IVD raw materials, technical services, and consulting—covering every stage from concept to clinic. This anti-Epac1/RAPGEF3 polyclonal antibody exemplifies our portfolio of cell-signaling and cardiovascular research reagents. We offer validated antibody pairs, bulk ancillary reagents, and tailored sourcing for rare targets, supporting seamless assay development and scale-up.